Tumor growth inhibition after Pasireotide (SOM230) in a rat prostate tumor model (DU-145) alone and in combination with Everolimus (RAD001)

被引：0
|
作者：
Schmid, Herbert A.
Paolo, Nuciforo
机构：
来源：
ENDOCRINE JOURNAL | 2010年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S589 / S589
页数：1
相关论文
共 13 条
  • [1] Antitumor Activity of Pasireotide (SOM230) alone and in Combination with Everolimus (RAD001) in DU-145 Human Prostate Cancer Model
    Schmid, H. A.
    Lambertini, C.
    Nuciforo, P.
    NEUROENDOCRINOLOGY, 2010, 92 (01) : 12 - 12
  • [2] Antitumor Activity of Pasireotide (SOM230) Alone and in Combination with Everolimus (RAD001) in DU-145 Human Prostate Cancer Model.
    Schmid, H. A.
    Lambertini, C.
    Nuciforo, P.
    ENDOCRINE REVIEWS, 2010, 31 (03)
  • [3] Inhibitory effect of pasireotide (SOM230) in a rat pancreatic tumor model (CA20948) alone and in combination with everolimus (RAD001)
    Schmid, Herbert
    Jensen, Michael
    CANCER RESEARCH, 2009, 69
  • [4] Phase I Study of Pasireotide (SOM230) in Combination With Everolimus (RAD001) in Patients With Advanced Neuroendocrine Tumors (NET)
    Chan, Jennifer A.
    Ryan, David P.
    Fuchs, Charles S.
    Zhu, Andrew X.
    Abrams, Thomas A.
    Wolpin, Brian M.
    Casey, Carolyn
    Regan, Eileen
    Cavanaugh, Kristen
    Kulke, Matthew H.
    PANCREAS, 2011, 40 (02) : 325 - 325
  • [5] Preclinical evidences suggest new treatment options for endocrine disorders: Pasireotide (SOM230) and Everolimus (RAD001)
    Schmid, H. A.
    ANNALES D ENDOCRINOLOGIE, 2008, 69 (02) : 162 - 163
  • [6] Updated results of a phase I study of pasireotide (SOM230) in combination with everolimus (RAD001) in patients (pts) with advanced neuroendocrine tumors (NET).
    Chan, J. A.
    Ryan, D. P.
    Fuchs, C. S.
    Zhu, A. X.
    Abrams, T. A.
    Wolpin, B. M.
    Malinowski, P.
    Regan, E.
    Kulke, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] Tumor oxygenation after hyperthermia in the rat 13762 mammary carcinoma and the DU-145 human prostate carcinoma
    Teicher, BA
    Ara, G
    Takeuchi, H
    Coleman, CN
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1997, 10 (03) : 437 - 442
  • [8] Metastasis after mTOR inhibition by RAD001 in a neuroendocrine rat tumor model: Combination therapy with 177Lu-DOTA, Tyr3-octreotate
    Pool, Stefan
    Koelewijn, Stuart
    Krenning, Eric
    de Jong, Marion
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52
  • [9] Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition
    Goudar, RK
    Shi, Q
    Hjelmeland, MD
    Keir, ST
    McLendon, RE
    Wikstrand, CJ
    Reese, ED
    Conrad, CA
    Traxler, P
    Lane, HA
    Reardon, DA
    Cavenee, WK
    Wang, XF
    Bigner, DD
    Friedman, HS
    Rich, JN
    MOLECULAR CANCER THERAPEUTICS, 2005, 4 (01) : 101 - 112
  • [10] Combination therapy of inhibitors of the epidermal growth factor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.
    Goudar, R
    Keir, S
    Hjelmeland, M
    Conrad, C
    Traxler, P
    Lane, H
    Wang, XF
    Bigner, DD
    Friedman, HS
    Rich, JN
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6090S - 6090S
12